bioMérieux Transfers Certain R&D and Manufacturing Activities to France

08 January, 2008

bioMérieux (Euronext: BIM) announces the transfer to France of R&D and certain manufacturing activities currently at its Boxtel site in the Netherlands. The transfer will take place gradually until the end of 2009, when this site closes.

All of the molecular diagnostics R&D and manufacturing will be transferred to the Christophe Mérieux Center in Grenoble, for a seamless interface between product development and manufacturing. A new plant will be built on the site to accommodate manufacturing of molecular diagnostic systems.

In parallel, microplate immunoassay R&D, together with the production of raw materials, will be moved to Marcy l’Etoile, the company’s global center of excellence for immunoassays. bioMérieux will communicate where this product line will be manufactured at a later date.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 40 years, bioMérieux is present in more than 150 countries through 36 subsidiaries and a large network of distributors. In 2006, revenues reached €1.037 billion with 83% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Euronext Paris. Other information can be found at

bioMérieux Contacts

Hervé Laurent
Tel: + 33 4 78 87 22 37

LT Value
Nancy Levain
Tel: + 33 1 44 50 39 30

Media Relations

Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08

Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64

Tiphaine Hecketsweiler
Tel: + 33 1 53 70 74 59

Pioneering Diagnostics